Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Whalewatcher1on Dec 27, 2021 9:53pm
82 Views
Post# 34264804

RE:RE:RE:Whalewatcher1 when you're going for the jugular don't miss!

RE:RE:RE:Whalewatcher1 when you're going for the jugular don't miss!Ok, so they have zero net income so can't use the net income standard in page 11 you are referring to. Thus equity standard requires $15M market cap. Yet they are only at $5,5M, so they need to raise $10M plus - 65% dilution. Take into account sizewblemdisicount needed. They always adds warrants on every deal so additional dilution.  Sorry but your calculations don't make any sense, this company is traded on OTC, you can't arbitrarily pick a IPO price. It's base on last trade on OTC.  I don't see how they list on Nasdaq without a massive dilutive raise and frankly would be difficult to find investors to put that kind of money with these guys . . . .

fwiw, what's there to really partner, first need positive data and issued patents that can actually block competitors
<< Previous
Bullboard Posts
Next >>